Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Steps to Effective Problem Solving in Group Homes

NCT02855008
View directory record Official record
Conditions
Problem Behavior
Interventions
STEPS, Food for Life
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Results available

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

NCT00590122
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Parcopa, carbidopa-levodopa (Sinemet)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
31 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes

NCT05527405
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Caregiver Burden, Assistive Technology
Interventions
The MapHabit System
Device
Lead sponsor
MapHabit, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

NCT00795418
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, CAD106
Biological
Lead sponsor
Novartis
Industry
Eligibility
40 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 6:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT06874621
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
VY7523, Placebo Comparator
Drug
Lead sponsor
Voyager Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

NCT05174806
View directory record Official record
Conditions
Diabetic Foot Infection, Diabetic Foot
Interventions
Topical Pravibismane, Standard of Care
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Fresno, California • Dallas, Texas • McAllen, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

NCT02784392
View directory record Official record
Conditions
Enteral Feeding Intolerance (EFI)
Interventions
Ulimorelin, Metoclopramide
Drug
Lead sponsor
Lyric Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New Orleans, Louisiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 23, 2026, 6:03 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
31
States / cities
Madison, Alabama • North Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches

NCT06112093
View directory record Official record
Conditions
Brain Concussion, Mild Traumatic Brain Injury, Headache, Post-Concussion Symptoms
Interventions
Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

NCT03691844
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
AMZ001, Placebo, Comparator
Drug
Lead sponsor
Amzell
Industry
Eligibility
40 Years to 85 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Milford, Connecticut • The Villages, Florida • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study on the Bioequivalence of Vitamin D in Healthy Adults

NCT03552666
View directory record Official record
Conditions
Bioequivalence of Vitamin D in Healthy Adults
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial for Harm Reduction With Incentives & Vaping E-cigarettes

NCT06111053
View directory record Official record
Conditions
Obesity, Smoking Cessation
Interventions
ENDS, CI, No ENDS, NI
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands

NCT04885322
View directory record Official record
Conditions
Healthy
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT03293992
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
0.01% RO7058584, 0.1% RO7058584, 1% RO7058584, Matching Placebo, Latanoprost 0.005%
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
8
States / cities
Chandler, Arizona • Artesia, California • Inglewood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 23, 2026, 6:03 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

NCT06077422
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use, Perioperative Complication, Heart Diseases
Interventions
bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcutaneous Vagus Nerve Stimulation (tVNS) and Stress Regulation During Performance Tasks

NCT07470229
View directory record Official record
Conditions
Stress Response
Interventions
Transcutaneous Vagus Nerve Stimulation (tVNS), Evaluative Stress Task
Device · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

NCT07867080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
49
States / cities
Scottsdale, Arizona • Encino, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SPG302 in Adults With Schizophrenia

NCT06442462
View directory record Official record
Conditions
Schizophrenia
Interventions
SPG302, Placebo
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT04770220
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801, Placebo Comparator: Placebo
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Jaguar LAA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Barriers to Physical Activity in People With Type 2 Diabetes

NCT01701570
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo Attention Control, Supervised Exercise Training
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 23, 2026, 6:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

NCT00375973
View directory record Official record
Conditions
Fatigue Syndrome, Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 23, 2026, 6:03 PM EDT